Markus B Schoenberg1, Svetlana Marx, Jan F Kersten, Thomas Rösch, Sebastian Belle, Georg Kähler, Melina C Vassiliou, Stefan Lüth, Daniel von Renteln. 1. *Department for General, Visceral, Thoracic and Transplant Surgery, University Medical Center, Leipzig †Central Interdisciplinary Endoscopy ‡Department for Gastroenterology and Hepatology, University Medical Center, Mannheim, Germany §Department for Biostatistics, Heidelberg University, Medical Faculty Mannheim, Germany ¶Department of Medical Biometry and Epidemiology ‖Department of Interdisciplinary Endoscopy **Department for Gastroenterology and Hepatology, University Medical Center, Hamburg-Eppendorf, Germany ††Department of Surgery, Montreal General Hospital, McGill University, Montreal, Québec, Canada.
Abstract
OBJECTIVE: Comparison of short- and long-term effects after laparoscopic Heller myotomy (LHM) and endoscopic balloon dilation (EBD) considering the need for retreatment. BACKGROUND: Previously published studies have indicated that LHM is the most effective treatment for Achalasia. In contrast to that a recent randomized trial found EBD equivalent to LHM 2 years after initial treatment. METHODS: A search in Medline, PubMed, and Cochrane Central Register of Controlled Trials was conducted for prospective studies on interventional achalasia therapy with predefined exclusion criteria. Data on success rates after the initial and repeated treatment were extracted. An adjusted network meta-analysis and meta-regression analysis was used, combined with a head-to-head comparison, for follow-up at 12, 24, and 60 months. RESULTS: Sixteen studies including results of 590 LHM and EBD patients were identified. Odds ratio (OR) was 2.20 at 12 months (95% confidence interval: 1.18-4.09; P = 0.01); 5.06 at 24 months (2.61-9.80; P < 0.00001) and 29.83 at 60 months (3.96-224.68; P = 0.001). LHM was also significantly superior for all time points when therapy included re-treatments [OR = 4.83 (1.87-12.50), 19.61 (5.34-71.95), and 17.90 (2.17-147.98); P ≤ 0.01 for all comparisons) Complication rates were not significantly different. Meta-regression analysis showed that amount of dilations had a significant impact on treatment effects (P = 0.009). Every dilation (up to 3) improved treatment effect by 11.9% (2.8%-21.8%). CONCLUSIONS: In this network meta-analysis, LHM demonstrated superior short- and long-term efficacy and should be considered first-line treatment of esophageal achalasia.
OBJECTIVE: Comparison of short- and long-term effects after laparoscopic Heller myotomy (LHM) and endoscopic balloon dilation (EBD) considering the need for retreatment. BACKGROUND: Previously published studies have indicated that LHM is the most effective treatment for Achalasia. In contrast to that a recent randomized trial found EBD equivalent to LHM 2 years after initial treatment. METHODS: A search in Medline, PubMed, and Cochrane Central Register of Controlled Trials was conducted for prospective studies on interventional achalasia therapy with predefined exclusion criteria. Data on success rates after the initial and repeated treatment were extracted. An adjusted network meta-analysis and meta-regression analysis was used, combined with a head-to-head comparison, for follow-up at 12, 24, and 60 months. RESULTS: Sixteen studies including results of 590 LHM and EBD patients were identified. Odds ratio (OR) was 2.20 at 12 months (95% confidence interval: 1.18-4.09; P = 0.01); 5.06 at 24 months (2.61-9.80; P < 0.00001) and 29.83 at 60 months (3.96-224.68; P = 0.001). LHM was also significantly superior for all time points when therapy included re-treatments [OR = 4.83 (1.87-12.50), 19.61 (5.34-71.95), and 17.90 (2.17-147.98); P ≤ 0.01 for all comparisons) Complication rates were not significantly different. Meta-regression analysis showed that amount of dilations had a significant impact on treatment effects (P = 0.009). Every dilation (up to 3) improved treatment effect by 11.9% (2.8%-21.8%). CONCLUSIONS: In this network meta-analysis, LHM demonstrated superior short- and long-term efficacy and should be considered first-line treatment of esophageal achalasia.
Authors: Juan Carlos Molina; Ana María Misariu; Ioana Nicolau; Jonathan Spicer; David Mulder; Lorenzo E Ferri; Carmen L Mueller Journal: Surg Endosc Date: 2017-08-04 Impact factor: 4.584
Authors: Oscar M Crespin; Louis W C Liu; Ambica Parmar; Timothy D Jackson; Jemila Hamid; Eran Shlomovitz; Allan Okrainec Journal: Surg Endosc Date: 2016-09-15 Impact factor: 4.584
Authors: Ezra N Teitelbaum; Christy M Dunst; Kevin M Reavis; Ahmed M Sharata; Marc A Ward; Steven R DeMeester; Lee L Swanström Journal: Surg Endosc Date: 2017-06-29 Impact factor: 4.584